Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE TNBC lacks of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), so there are still no effective treatment methods for TNBC. 31761352 2020
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 AlteredExpression disease BEFREE We showed that LINC00908 was directly regulated by ERα, which was responsible for the differential down-regulation of LINC00908 in TNBCs. 31816634 2020
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE Fifteen patients had triple-negative breast cancer (estrogen receptor/progesterone receptor < 10%), and five had hormone receptor-positive disease. 31461380 2020
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE Moderate supplemental vitamin D intake was associated with decreased risk of TNBC, and increased sun exposure was associated with reduced risk of ER+, ER-, and TNBC among black women. 31826233 2020
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE Triple negative breast cancer (TNBC) refers to breast cancer that lacks progesterone receptor (PR), estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2). 31786854 2020
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 AlteredExpression disease BEFREE Triple negative breast cancer is characterized by lack of expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2), high histologic grade, and high mitotic rate. 31155832 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE Triple-negative breast cancer (TNBC) is insensitive to endocrine therapies and targeted therapies to human epidermal growth factor receptor-2 (HER2), estrogen receptor (ER) and progesterone receptor (PR). 30289981 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE In this study, we designed a therapeutic strategy using a combination of a low dose of paclitaxel and a Wnt signaling inhibitor (XAV939), and examined the effect of the paclitaxel-combined XAV939 treatment on diverse breast cancer lines including TNBC cell lines (MDA-MB-231, MDA-MB-468, and BT549) and ER+ve cell lines (MCF-7 and T-47D). 31416135 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE Triple-negative breast cancer (TNBC) is characterized by the lack of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2). 30660004 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE <b>Background:</b> Triple-negative breast cancer (TNBC) is a breast cancer that tests negative for estrogen receptor (ER), progesterone receptors, and human epidermal growth factor receptors 2 (HER2). 31839713 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 AlteredExpression disease BEFREE Triple Negative breast cancer (TNBC) is a poor outcome subgroup of breast cancer defined based on the absence of expression of ERα and PR and HER2 amplification. 30935371 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 AlteredExpression disease BEFREE Triple-negative breast cancer (TNBC) lacks the expressions of estrogen receptor-α, progesterone receptor and human epidermal growth factor receptor-2. 31186742 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 AlteredExpression disease BEFREE Triple negative breast cancer (TNBC), which is typically lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), represents the most aggressive and mortal subtype of breast cancer. 31088482 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE Currently, traditional predictors of prognosis (tumor size, nodal status, progesterone receptor [PR], estrogen receptor [ER], or human epidermal growth factor receptor-2 [HER2]) are insufficient for precise survival prediction for triple-negative breast cancer (TNBC). 30203490 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE Current standard-of-care (SOC) therapy for breast cancer includes targeted therapies such as endocrine therapy for estrogen receptor-alpha (ERα) positive; anti-HER2 monoclonal antibodies for human epidermal growth factor receptor-2 (HER2)-enriched; and general chemotherapy for triple negative breast cancer (TNBC) subtypes. 30691108 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 GeneticVariation disease BEFREE American women of African ancestry (AA) are more likely than those of European ancestry (EA) to be diagnosed with aggressive, estrogen receptor negative (ER-) or triple negative breast cancer, and to die of this disease. 30321299 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE Estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-positive, and TNBC subtypes were included in the analyses. 30725384 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 AlteredExpression disease BEFREE Triple-negative breast cancer (TNBC) is characterized by a lack of expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) and unfortunately is not associated with good prognosis. 31570423 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 GeneticVariation disease BEFREE Triple-negative breast cancer (TNBC), which lacks estrogen receptor α (ERα), progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expression, is closely related to basal-like breast cancer. 31704972 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE Specific subtypes of breast cancer such as estrogen receptor (ER)-negative, human EGF receptor 2 (HER2)-positive, and triple-negative breast cancer (TNBC) have shown evidence of immunogenicity based on tumor-immune interactions. 30697064 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE <b>Rationale:</b> Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor alpha (ER-α), human epidermal growth factor receptor 2 (HER2) and progesterone receptor (PR) expression, but the effect of lacking the three factors on TNBC is unclear. 30867840 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE Interestingly, we found increased ROS levels in triple negative breast cancer (TNBC) cell lines and a dependency on ROS for survival since antioxidant treatment induced cell death in TNBC cells but not in an estrogen receptor positive (ER+) cell line. 31231612 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE Numerous studies have demonstrated the effectiveness of resveratrol in estrogen receptor‑positive (ER‑positive) subtypes of breast cancer, yet the effects in ER‑negative subtypes, including triple‑negative breast cancer (TNBC), have been limited. 31002359 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE Expression of MDM2 and MDMX occurs in estrogen receptor α-positive (ERα<sup>+</sup>) breast cancer and triple-negative breast cancer (TNBC). 30642351 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE In this study, we demonstrated an elevated expression of PTTG3P in breast cancer and discovered that PTTG3P expression correlated negatively with estrogen receptor (ER) and progesterone receptor (PR) status, but linked positively to basal-like status, triple-negative breast cancer status, Nottingham prognostic index (NPI)<b>,</b> and Scarff-Bloom-Richardson grade. 31011629 2019